Download Presentation - UNC Lineberger Comprehensive Cancer Center

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Bringing the Patient Voice into
Cancer Care and Research
Ethan Basch, MD, MSc
November 19, 2015
Symptoms
• Common and often debilitating in cancer
• Recognizing symptoms is a key role of doctors
and nurses
– During cancer treatment
– In clinical trials
Symptoms Often Go Undetected
• Up to half of
patients’ symptoms
are missed during
cancer treatment
Patientreported
Fatigue
Anorexia
Nausea
Vomiting
Clinicianreported
Months
3Months
Serious Implications
• Under-management of symptoms during
cancer treatment
• Under-documentation of symptoms and side
effects in clinical trials
Research on “Patient-Reported Outcomes”
• Develop questionnaires and software to
enable patient self-reporting of symptoms,
physical functioning and “quality of life”
• Test these approaches during routine
chemotherapy care and in clinical trials
nationally
• Work closely with NCI, FDA,
pharmaceutical industry, etc.
UNC is a National Leader in this Area
• Angie Smith, MD
• Arlene Chung, MD
• Bryce Reeve, PhD
• Antonia Bennett, PhD
• Bill Wood, MD
• Hy Muss, MD
• Grant Williams, MD
Examples
Pain
• Common in cancer, not well controlled
– Reported by 2/3 patients with advanced disease
• Inadequate analgesics among 1/3
Particularly True in Prostate Cancer
More than half with
advanced disease report
clinically meaningful
pain (>4 on 0-10 NRS)
1996
• Approved based on an old patient pain questionnaire
1997-2014
• Only 1 other oncology drug approved by FDA based
on patient-reported information (Ruxolitinib, 2011)
• Surprising, given how common symptoms and
functional impairment are in oncology
Why So Rare?
FDA introduced a “PRO
Guidance”
U.S. Food &
Drug
Administration
Outlined standards
- Patient interviews
- Testing
- Relevance to trials
- Implementation, analysis
Groundbreaking… but overly
stringent, and industry was
largely unwilling and unable to
adhere in most cases
Researcher Role
• Worked with FDA on approach to PROs in oncology
–
–
–
–
–
–
Outcome: pain intensity
Measure: 0-10 NRS (BPI)
Recall: 24 hours
Meaningful change: 30% or 2 points
Analgesic use: integrated into design
Analysis approaches
Work with Industry
Work with Consensus Groups
Work with National Clinical Practice Guidelines
A Second Example
• Measuring symptom side effects in clinical
trials
– Clinicians miss many of these
– UNC researchers led development of approach for
patients to report their own side effects
• Developed for the National Cancer Institute
• Called the “PRO-CTCAE”
Developed/Tested Questionnaire and Software
Shows Better Symptom Detection in Trials
Clinician Reporting
Patient Reporting
Improves Outcomes during Treatment
• Improved QOL, longer chemotherapy, fewer ER visits
Recent Publications on PRO-CTCAE
Support PRO Software for Many Trials
• UNC Cancer Center “PRO-Core"
Patient-Centered Approaches to Quality of Care
Standards for PatientReported Outcome-based
Performance Measures
PROs in Geriatrics
• Key to measure the patient experience –
risk of comorbidities; functional impairments
– E.g., the GA
• Older patients are enthusiastic to self-report
• Enables communication
• Methods research considerations
– What outcomes, how ask questions, how often,
how use the information, how report results?
– Requires interdisciplinary collaboration
Thank You